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Some authors afﬁrm that early liver transplant (LT) provides
excellent short-term survival in patients with severe alcoholic
hepatitis (SAH) (1–4) and similar rates of alcohol relapse
compared to patients with 6 months of abstinence. We
agree with the choice of not excluding patients who manifest
their decompensation with bleeding and infections (common
complications of SAH) and patients with psychiatric comor-
bidities. Data from the literature have stated for a long time
that the approach to patients with alcoholic liver disease
(ALD) should be changed with no ethical or technical precon-
ceptions. The reasons in favor of this change are as follows:
1) ALD is common: it is responsible for 80% of deaths from
liver disease and 50% of deaths from cirrhosis (5).
2) It is the second cause of LT, and with the arrival of
direct-acting antiviral drugs, it will become the primary
cause.
3) Relapse post-LT varies from 11% to 50%, but a loss of
graft occurs in less than 17% of cases and death in less
than 5% of cases (6).
4) Mathurin et al. (1) have brought an innovation to LT
indication: 26 patients were listed for LT (average age
47.4 years), who had not responded to steroidal therapy
(average time 13 days). Six-month survival was 77%
(compared with 23% in a nonrandomized case-matched
control group). It is important to also remember the
experience of Singal et al. (7). They ﬁrst compared the
survival of post-LT patients with alcoholic hepatitis (11
cases, days waiting for LT 67 ± 86) and of patients
with alcoholic cirrhosis (35 cases, days waiting for LT
145 ± 340). The 5-year graft and patient survival of
alcoholic hepatitis were 75% and 73% (P=0.97), and
for alcoholic cirrhosis it was 80% and 78% (P=0.90),
respectively.
We have experience of seven nonresponder patients (median
age 49 years), with clinical evidence of SAH and type 1 hepa-
torenal syndrome, receiving a transjugular intrahepatic por-
tosystemic shunt and then being successfully transplanted.
SAH was histologically diagnosed in the removed liver. No
patients had an alcoholic relapse post-LT (8). We think that
LT indication without the 6-month rule should also be
extended to patients with progressive end-stage liver disease
(ESLD) who come to the transplant team for the ﬁrst time
and who do not improve after a 3-month abstinence period.
In 2014, an Italian position statement (6) suggested propo-
sals to ensure the right balance between ethics and clinical
success (9–12). The proposals in relation to the complex
population of ALD patients are as follows:
1) Patients with SAH can be placed on an LT list if it is their
ﬁrst episode, if there is no response to medical therapy
with steroids, and if family and environmental supports
are available.
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2) Patients with progressive ESLD (a model ESLD score
[MELD score] equal to or greater than 19) may be placed
on the list if after 3 months of abstinence there is no clin-
ical regression.
3) Patients with aMELD of <19 and who have been treated
at an alcohol rehabilitation center for some time must
ensure 6 months of abstention.
From these proposals, it becomes clear that the “6-month”
rule should not be considered as dogmatic. However, for
the optimal management of these patients, a change of hepa-
tology services is needed. Patients, in fact, are affected by a
double pathology: alcohol dependence and ALD. Patients
should be seen in a nonjudgmental environment made up of
professionals with appropriate psycho-relational skills. This
provides a closer adherence to the path of care and greater
motivation for abstention from alcohol, both pre- and
post-LT.
Collaboration with self-help groups (SHGs) is necessary,
particularly during the post-LT period, to ensure abstention.
However, in a multidisciplinary team, the presence of an
addiction specialist and a hepatologist with well-deﬁned alco-
hological experience is needed.
Addolorato et al. (13) suggested how the presence of an
addiction unit could be useful. This allows the addition of
patients onto an LT list independently of the 6-month absten-
tion period with a reduction in deaths caused by a wait that is
sometimes too long in relation to their serious medical condi-
tions.
Therefore, even though ALD is a self-inﬂicted pathology,
in a society that promotes the consumption of alcohol in rela-
tion to success, sport, and well-being, we have a duty to
ensure patient care. A new way of working in managing
patients with alcohol dependence and liver pathology is
needed. During the post-LT phase in particular, the patient
must be surrounded by a network of protection where health
practitioners and families cooperate closely with the indispen-
sable actions of SHGs. This allows the avoidance of alcoholic
relapse in a high percentage of cases and, therefore, indirectly
the preservation of the graft. In addition, during the post-LT
period, adequate treatment of metabolic syndrome (MS) and
close oncological surveillance are necessary. Cardiovascular
complications and tumors are the most frequent causes of
death in transplant patients with ALD. One year post-LT,
90% of cases develop at least one factor of MS (obesity,
hypertension, dyslipidemia, or hyperglycemia); on the con-
trary, alcohol-related oncological risk decreases by about
10% per year (14). Ethanol, in fact, has been placed in
Group 1 by the International Agency for Research on Cancer
(IARC)—World Health Organization (15).
In conclusion, according to Lee et al. (4), it is necessary to
validate models that can help us predict eventual alcoholic
relapse post-LT, and it is even more important to review
hepato-alcohological activity in transplant teams.
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